Company: DMAC
Filing Date: 2025-08-12
Form Type: 8-K
Source: 0001437749-25-026286
Chunk: 1

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: 8-K
Item: Item 1.01
Chunk 1
---
 shall there be any sale of the ATM Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction.

The ATM Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-[_]), filed with the SEC on August 12, 2025. The shelf registration statement has not yet been declared effective by the SEC and no sales may be made until such time as the shelf registration statement is declared effective. The Company will file a final prospectus supplement with the SEC following the effectiveness of the shelf registration statement relating to the offer and sale of the shares pursuant to the Sales Agreement.

A copy of the Sales Agreement is incorporated herein by reference. The foregoing description of the material terms of the Sales Agreement is not complete and is qualified in its entirety by reference to such exhibit.

Pushor Mitchell, counsel to the Company, has issued a legal opinion relating to the ATM Shares. A copy of such legal opinion, including the consent included therein, is incorporated herein by reference.

Alston & Bird LLP, counsel to the Company, has also issued a legal opinion relating to the ATM Shares. A copy of such legal opinion, including the consent included therein, is incorporated herein by reference.

  Item 9.01.      Financial Statements and Exhibits.  

  (d)      Exhibits.  

The following exhibit is furnished herewith:

  Exhibit                                                                                                                                                                                                            
   Number      Description                                                                                                                                                                                           
      5.1      Opinion of Pushor Mitchell (Incorporated by reference to Exhibit 5.1 to DiaMedica’s Form S-3 filed on August 12, 2025.)                                                                               
      5.2      Opinion of Alston & Bird LLP (Incorporated by reference to Exhibit 5.2 to DiaMedica’s Form S-3 filed on August 12, 2025.)                                                                             
     10.1      Sales Agreement between DiaMedica Therapeutics Inc. and TD Securities (USA) LLC, dated August 12, 2025. (Incorporated by reference to Exhibit 1.2 to DiaMedica’s Form S-3 filed on August 12, 2025.)  
     23.1      Consent of Pushor Mitchell (included in the opinion filed as Exhibit 5.1) (Incorporated by reference to Exhibit 5.1 to DiaMedica’s Form